Abstract
CK-571 is a recently developed smooth muscle and non-muscle (NM2) myosin specific compound inhibiting them with IC50 = 9 nM and 100 nM while cardiac and skeletal muscle myosins are inhibited with several magnitude weaker binding. CK-571 might have great medical potential in several diseases related to smooth muscle myosin and NM2 functions. We have synthesized several derivatives of CK-571 introducing structural modifications in its linker region. We tested these derivatives on skeletal, smooth, cardiac and NM2 A, B, C myosin isoforms. Our results may open novel perspectives in developing novel smooth and NM2 specific drug derivatives.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
